TCRT

Alaunos Therapeutics Inc

Add to Watchlist

Advanced Chart

2.630

-0.050(-1.870%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.860

Open

2.690

VWAP

2.71

Vol

17.82K

Mkt Cap

4.31M

Low

2.560

Amount

48.33K

EV/EBITDA(TTM)

Total Shares

16.01M

3.22M

EV/OCF(TTM)

P/S(TTM)

414.72

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. It is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. It is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q2

0.00

-100%

Estimates Revision

Stock Price

Go Up

+58.91%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT.O) is -0.27, compared to its 5-year average forward P/E of -4.50. For a more detailed relative valuation and DCF analysis to assess Alaunos Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.50

Current PE

-0.27

Overvalued PE

-1.65

Undervalued PE

-7.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.33

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.48

Undervalued EV/EBITDA

-4.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3264.33

Current PS

0.00

Overvalued PS

12783.11

Undervalued PS

-6254.45